logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Shandong Molong (00568.HK) announced its first three quarters results, with a net loss attributable to shareholders of RMB 95.1786 million.

date
27/10/2026
Zhitong Finance APP News, Shandong Molong (00568.HK) released its performance for the first three quarters of 2026. The Group achieved operating revenue of RMB 1.769 billion, a year-on-year increase of 48.05%; net loss attributable to shareholders of the listed company was RMB 95.1786 million; basic loss per share was RMB 0.1184.
Latest
2 m ago
CSPC Pharmaceutical Group (01093.HK): The Phase I/II clinical study results of SYS6043 (B7-H3 ADC) for the treatment of advanced breast cancer were presented as a rapid oral presentation at the 2026 ESMO Congress.
2 m ago
Jinyuan Co., Ltd. (000546.SZ) released its performance for the first three quarters, with a net loss attributable to shareholders of RMB 225 million.
6 m ago
Zhejiang University Insigma (600797.SH) released its first three quarters performance, with a net loss attributable to shareholders of RMB 59.39 million.
6 m ago
Norwegian Cruise Line and Carnival Cruise Line shares erase losses, turn positive in premarket.
6 m ago
CSPC Pharmaceutical Group (01093.HK): Results from the Phase I/II Clinical Study of the Anti-PD-1/IL-15 Bifunctional Fusion Protein SYS6090 (JMT108) as Monotherapy for Advanced Solid Tumors Presented as a Rapid Oral Presentation at the 2026 ESMO Congress
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.